Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily ...

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

Macau Drug Administration approves Belief Pharmaceuticals’ haemophilia B gene therapy drug, Popidacoji injection: Shanghai, China Saturday, March 21, 2026, 17:00 Hrs [IST] Belie ...

SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical ...

For many families living with haemophilia, a simple fall or minor injury can quickly become a life and death situation. The inherited bleeding disorder, which prevents the blood from clotting ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia B pipeline constitutes 15+ key companies continuously working towards developing 20+ ...

New research shows epigenetic silencing may limit durability of AAV gene therapy in haemophilia by reducing long term transgene expression in liver cells.

Dr. Sanjay P. Ahuja shares insight into Innovative Hematology’s Gene Therapy Hub, the first of its kind in Indiana.

The bottom line: We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades.

The global healthcare landscape is witnessing a transformative shift in the management of rare genetic disorders. At the forefront of this evolution stands the Hemophilia Therapeutics Market. This ...

The day care centre at MKCG Medical College and Hospital Berhampur: Over 150 registered haemophilia patients in Ganjam district are struggling due to a shortage of clotting-factor injections at MKCG ...